New research shows 36% reduction in 30-day hospital readmission rate for dario users with type 2 diabetes

New research demonstrates dario's ability to reduce costs through lower utilization of expensive healthcare resources, and the winning of a prestigious gold ribbon award new york , oct. 17, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today new research presented by sanofi u.s. at the academy of managed care pharmacy's 2023 annual conference nexus ("amcp-nexus"), demonstrating a 36% reduction in 30-day hospital readmissions for dario users compared to non-users living with type 2 diabetes.   research demonstrates significant reductions in costly utilization metrics new data presented by sanofi u.s. at amcp-nexus examined matched dario users and non-users with type 2 diabetes to understand the impact of dario's digital health solution.
DRIO Ratings Summary
DRIO Quant Ranking